RPRX N Stock Overview
Operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 3/6 |
| Financial Health | 4/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
Royalty Pharma plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$528.50 |
| 52 Week High | US$586.00 |
| 52 Week Low | US$448.33 |
| Beta | 0.47 |
| 11 Month Change | -3.91% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | -30.89% |
| 5 Year Change | n/a |
| Change since IPO | -35.55% |
Recent News & Updates
Recent updates
Shareholder Returns
| RPRX N | MX Pharmaceuticals | MX Market | |
|---|---|---|---|
| 7D | 0% | -0.3% | -1.3% |
| 1Y | n/a | -18.8% | -4.0% |
Return vs Industry: Insufficient data to determine how RPRX N performed against the MX Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how RPRX N performed against the MX Market.
Price Volatility
| RPRX N volatility | |
|---|---|
| RPRX N Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.7% |
| Market Average Movement | 4.1% |
| 10% most volatile stocks in MX Market | 6.2% |
| 10% least volatile stocks in MX Market | 2.6% |
Stable Share Price: RPRX N's share price has been volatile over the past 3 months compared to the MX market.
Volatility Over Time: Insufficient data to determine RPRX N's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | n/a | Pablo Legorreta | www.royaltypharma.com |
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.
Royalty Pharma plc Fundamentals Summary
| RPRX N fundamental statistics | |
|---|---|
| Market cap | Mex$313.63b |
| Earnings (TTM) | Mex$23.25b |
| Revenue (TTM) | Mex$46.00b |
10.2x
P/E Ratio5.1x
P/S RatioIs RPRX N overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RPRX N income statement (TTM) | |
|---|---|
| Revenue | US$2.27b |
| Cost of Revenue | US$491.91m |
| Gross Profit | US$1.77b |
| Other Expenses | US$628.98m |
| Earnings | US$1.15b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.58 |
| Gross Margin | 78.29% |
| Net Profit Margin | 50.53% |
| Debt/Equity Ratio | 74.2% |
How did RPRX N perform over the long term?
See historical performance and comparisonDividends
3.2%
Current Dividend Yield32%
Payout RatioDoes RPRX N pay a reliable dividends?
See RPRX N dividend history and benchmarks| Royalty Pharma dividend dates | |
|---|---|
| Ex Dividend Date | Nov 15 2024 |
| Dividend Pay Date | Dec 10 2024 |
| Days until Ex dividend | 7 days |
| Days until Dividend pay date | 18 days |
Does RPRX N pay a reliable dividends?
See RPRX N dividend history and benchmarks